Basic Information
RNALocate ID: | RLID:11001799 |
RNA Symbol: | hsa-miR-143-3p |
Localization: | Exosome |
RNA Information
RNA Name: | hsa-miR-143-3p |
RNA ID: | miRBase:MIMAT0000435 |
RNA Category: | miRNA |
Species: | Homo sapiens |
Localization Information
PubMed ID: | 22211110 |
Tissue/Cell Line: | Breast milk |
Method: | Next-generation RNA sequencing |
The expression profile of selected miRNAs in breast milk exosomes. Originally published in Int J Biol Sci. Zhou Q, et al, 2012. Reproduced under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) |
|
Description: | Distribution and characterization of miRNAs in breast milk exosomes. (A) Distribution of pre-miRNAs. Out of 1,424 pre-miRNAs deposited in miRBase 17.0 (blue circle), 87 (6.11%) pre-miRNAs have been designated as immune-related pre-miRNAs based on annotation in the Pathway Central database (SABiosciences, MD, USA). Immune-related pre-miRNAs (59 of 452, 13.05%) are enriched in breast milk exosomes (red circle). χ2 test: Number of immune-related miRNAs and others detected in breast milk exosomes compared with the total entries in miRBase 17.0. (B) Top ten most highly expressed unique miRNAs. Plot of the unique miRNAs (starting from the miRNA with the highest counts, x-axis) versus their cumulative % of the total counts from 602 unique miRNAs detected in breast milk exosomes for each small RNA library. Values are means ± s.d. The dashed horizontal line at 62.3% represents the level of the top ten unique miRNAs and the % of individual miRNAs is marked by the gray line. (C-E) The expression profile of selected miRNAs in breast milk exosomes. (C) 59 immune-related pre-miRNAs; (D) miR-17-92 cluster and paralogous clusters, and (E) ten well-characterized tissue-specific pre-miRNAs. Data are collected from Figure 2. |
Other Subcellular Localization
RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
RLID:01001787 | Cytoplasm | Luminal cells|Stromal cells | 29073169 |
RLID:01001788 | Nucleus | Stromal cells | 29073169 |
RLID:11001797 | Exosome | Human cervical cancer cell line (HeLa) | 25760330 |
RLID:11001798 | Exosome | EBV- and KSHV-negative Burkitt lymphoma cell line (Bjab)|EBV-infected lymphoblastoid cell line (LCL)|KSHV-infected lymphoma cell lines (BCBL-1|TY-1) | 27611973 |
RLID:11001800 | Exosome | Brain tissue | 23382797 |
RLID:11001801 | Exosome | Plasma | 23663360 |
RLID:11001802 | Exosome | B cell lymphoma cell lines|EBV-transformed lymphoblastoid B cells | 25242326 |
RLID:11001803 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
RLID:11001804 | Exosome | Serum | 25349172 |
RLID:11001805 | Exosome | Cerebrospinal fluid | 25420022 |
RLID:11001806 | Extracellular vesicle | Human umbilical vein endothelial cells | 22327366 |
RLID:11001807 | Extracellular vesicle | HEK-293T cells | 22849433 |
RLID:11001808 | Microvesicle | Plasma | 23077538 |
RLID-D:11000085 | Exosome | Blood|B lymphoblastoid cells|Breast milk|Chronic lymphocytic leukemia cells|Endothelial cells|Lymphoma tissue|Mast cells|Saliva | |
RLID-D:11000363 | Microvesicle | Blood|Breast cell line|Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
Resource | RNA Symbol | Disease | Link |
MNDR | hsa-miR-143-3p | Diffuse large b cell lymphoma | MNDR-E-MI-14258 |
MNDR | hsa-miR-143-3p | Splenic marginal zone lymphoma | MNDR-E-MI-14259 |
MNDR | hsa-miR-143-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-14260 |
MNDR | hsa-miR-143-3p | Colorectal adenoma | MNDR-E-MI-14261 |
MNDR | hsa-miR-143-3p | Oral squamous cell carcinoma | MNDR-E-MI-14262 |
MNDR | hsa-miR-143-3p | Large cell neuroendocrine cancer | MNDR-E-MI-14263 |
MNDR | hsa-miR-143-3p | Medulloblastoma | MNDR-E-MI-14264 |
MNDR | hsa-miR-143-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-14265 |
MNDR | hsa-miR-143-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-14266 |
MNDR | hsa-miR-143-3p | Lymphoma | MNDR-E-MI-14267 |
MNDR | hsa-miR-143-3p | Lymphoma non-hodgkin | MNDR-E-MI-14268 |
MNDR | hsa-miR-143-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-14269 |
MNDR | hsa-miR-143-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-14270 |
MNDR | hsa-miR-143-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-14271 |
MNDR | hsa-miR-143-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-14272 |
MNDR | hsa-miR-143-3p | Her2-receptor positive breast cancer | MNDR-E-MI-14273 |
MNDR | hsa-miR-143-3p | Breast cancer luminal | MNDR-E-MI-14274 |
MNDR | hsa-miR-143-3p | Niemann-pick disease type c | MNDR-E-MI-14275 |
MNDR | hsa-miR-143-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-14276 |
MNDR | hsa-miR-143-3p | Colorectal carcinoma | MNDR-E-MI-14277 |
MNDR | hsa-miR-143-3p | Neurofibromatosis 1 | MNDR-E-MI-14278 |
MNDR | hsa-miR-143-3p | Bone metastasis of prostate cancer | MNDR-E-MI-14279 |
MNDR | hsa-miR-143-3p | B-cell malignancy | MNDR-E-MI-14280 |
MNDR | hsa-miR-143-3p | Gastric cancer | MNDR-E-MI-14281 |
MNDR | hsa-miR-143-3p | Gastric lymphoma | MNDR-E-MI-14282 |
MNDR | hsa-miR-143-3p | Alzheimer disease | MNDR-E-MI-14283 |
MNDR | hsa-miR-143-3p | Intracranial aneurysm | MNDR-E-MI-14284 |
MNDR | hsa-miR-143-3p | Bladder cancer | MNDR-E-MI-14285 |
MNDR | hsa-miR-143-3p | Esophageal carcinoma | MNDR-E-MI-14286 |
MNDR | hsa-miR-143-3p | Dysautonomia familial | MNDR-E-MI-14287 |
MNDR | hsa-miR-143-3p | Duchenne muscular dystrophy | MNDR-E-MI-14288 |
MNDR | hsa-miR-143-3p | Head and neck cancer | MNDR-E-MI-14289 |
MNDR | hsa-miR-143-3p | Leukemia | MNDR-E-MI-14290 |
MNDR | hsa-miR-143-3p | Huntington disease | MNDR-E-MI-14291 |
MNDR | hsa-miR-143-3p | Chorea | MNDR-E-MI-14292 |
MNDR | hsa-miR-143-3p | Cardiovascular disease | MNDR-E-MI-14293 |
MNDR | hsa-miR-143-3p | Lung cancer | MNDR-E-MI-14294 |
MNDR | hsa-miR-143-3p | Parkinson disease | MNDR-E-MI-14295 |
MNDR | hsa-miR-143-3p | Niemann-pick disease | MNDR-E-MI-14296 |
MNDR | hsa-miR-143-3p | Colonic adenomas | MNDR-E-MI-14297 |
MNDR | hsa-miR-143-3p | Basal-like breast cancer | MNDR-E-MI-14298 |
MNDR | hsa-miR-143-3p | Cancer | MNDR-E-MI-14299 |
MNDR | hsa-miR-143-3p | Squamous cell carcinoma | MNDR-E-MI-14300 |
MNDR | hsa-miR-143-3p | Vascular diseases | MNDR-E-MI-14301 |
MNDR | hsa-miR-143-3p | Pituitary neoplasms | MNDR-E-MI-14302 |
MNDR | hsa-miR-143-3p | Pancreatic cancer | MNDR-E-MI-14303 |
MNDR | hsa-miR-143-3p | Malignant melanoma | MNDR-E-MI-14304 |
MNDR | hsa-miR-143-3p | Atherosclerosis | MNDR-E-MI-14305 |
MNDR | hsa-miR-143-3p | Rectum adenocarcinoma | MNDR-E-MI-14306 |
MNDR | hsa-miR-143-3p | Nephroblastoma | MNDR-E-MI-14307 |
MNDR | hsa-miR-143-3p | Colon cancer | MNDR-E-MI-14308 |
MNDR | hsa-miR-143-3p | Colon adenocarcinoma | MNDR-E-MI-14309 |
MNDR | hsa-miR-143-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-14310 |
MNDR | hsa-miR-143-3p | Ovarian cancer | MNDR-E-MI-14311 |
MNDR | hsa-miR-143-3p | Prostate adenocarcinoma | MNDR-E-MI-14312 |
MNDR | hsa-miR-143-3p | Kidney cancer | MNDR-E-MI-14313 |
MNDR | hsa-miR-143-3p | Carcinoma ductal breast | MNDR-E-MI-14314 |
MNDR | hsa-miR-143-3p | Glioblastoma | MNDR-E-MI-14315 |
MNDR | hsa-miR-143-3p | Glioma | MNDR-E-MI-14316 |
MNDR | hsa-miR-143-3p | Chordoma | MNDR-E-MI-14317 |
MNDR | hsa-miR-143-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-14318 |
MNDR | hsa-miR-143-3p | Osteosarcoma | MNDR-E-MI-14319 |
MNDR | hsa-miR-143-3p | Ewing sarcoma family tumor | MNDR-E-MI-14320 |
MNDR | hsa-miR-143-3p | Liposarcoma | MNDR-E-MI-14321 |
MNDR | hsa-miR-143-3p | Peripheral vascular disease | MNDR-E-MI-14322 |
MNDR | hsa-miR-143-3p | Inclusion body myositis | MNDR-E-MI-14323 |
MNDR | hsa-miR-143-3p | Breast carcinoma | MNDR-E-MI-14324 |
MNDR | hsa-miR-143-3p | Pancreatic ductal adenocarcinoma | MNDR-E-MI-14325 |
MNDR | hsa-miR-143-3p | Meningioma | MNDR-E-MI-14326 |
MNDR | hsa-miR-143-3p | Liver cancer | MNDR-E-MI-14327 |
MNDR | hsa-miR-143-3p | Uterine cancer | MNDR-E-MI-14328 |
MNDR | hsa-miR-143-3p | Gastric adenocarcinoma | MNDR-E-MI-14329 |
MNDR | hsa-miR-143-3p | Cervical squamous cell carcinoma | MNDR-E-MI-14330 |
MNDR | hsa-miR-143-3p | Pituitary adenoma | MNDR-E-MI-14331 |
MNDR | hsa-miR-143-3p | Lung squamous cell carcinoma | MNDR-E-MI-14332 |
MNDR | hsa-miR-143-3p | Lung adenocarcinoma | MNDR-E-MI-14333 |
MNDR | hsa-miR-143-3p | Thyroid carcinoma | MNDR-E-MI-14334 |
MNDR | hsa-miR-143-3p | Ovarian carcinoma | MNDR-E-MI-14335 |
MNDR | hsa-miR-143-3p | Bladder urothelial carcinoma | MNDR-E-MI-14336 |
MNDR | hsa-miR-143-3p | Bladder carcinoma | MNDR-E-MI-14337 |
MNDR | hsa-miR-143-3p | Pancreatic adenocarcinoma | MNDR-E-MI-14338 |
MNDR | hsa-miR-143-3p | Cervical cancer | MNDR-E-MI-14339 |
MNDR | hsa-miR-143-3p | Carcinoma renal cell | MNDR-E-MI-14340 |
MNDR | hsa-miR-143-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-14341 |
MNDR | hsa-miR-143-3p | Clear cell renal cell carcinoma | MNDR-E-MI-14342 |
MNDR | hsa-miR-143-3p | Chromophobe renal cell carcinoma | MNDR-E-MI-14343 |
MNDR | hsa-miR-143-3p | Large cell carcinoma | MNDR-E-MI-14344 |
MNDR | hsa-miR-143-3p | Cholangiocarcinoma | MNDR-E-MI-14345 |
MNDR | hsa-miR-143-3p | Gallbladder carcinoma | MNDR-E-MI-14346 |
MNDR | hsa-miR-143-3p | Esophageal cancer | MNDR-E-MI-14347 |
MNDR | hsa-miR-143-3p | Lung small cell carcinoma | MNDR-E-MI-14348 |
MNDR | hsa-miR-143-3p | Encephalopathy bovine spongiform | MNDR-E-MI-14349 |
MNDR | hsa-miR-143-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-14350 |
MNDR | hsa-miR-143-3p | Uveal melanoma | MNDR-E-MI-14351 |
MNDR | hsa-miR-143-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-14352 |
MNDR | hsa-miR-143-3p | Fibromyalgia | MNDR-E-MI-14353 |
MNDR | hsa-miR-143-3p | Adenoma | MNDR-E-MI-14354 |
MNDR | hsa-miR-143-3p | Breast invasive carcinoma | MNDR-E-MI-14355 |
MNDR | hsa-miR-143-3p | Cerebrovascular disease | MNDR-E-MI-14356 |
MNDR | hsa-miR-143-3p | Hepatocellular carcinoma | MNDR-E-MI-14357 |
MNDR | hsa-miR-143-3p | B-cell lymphoma | MNDR-E-MI-14358 |
MNDR | hsa-miR-143-3p | Rheumatoid arthritis | MNDR-E-MI-14359 |
MNDR | hsa-miR-143-3p | T-cell leukemia | MNDR-E-MI-14360 |
MNDR | hsa-miR-143-3p | Chronic kidney disease | MNDR-E-MI-14361 |
MNDR | hsa-miR-143-3p | Barrett's adenocarcinoma | MNDR-E-MI-14362 |
MNDR | hsa-miR-143-3p | Chronic fatigue syndrome | MNDR-E-MI-14363 |
MNDR | hsa-miR-143-3p | Hodgkin lymphoma | MNDR-E-MI-14364 |
MNDR | hsa-miR-143-3p | Burkitt lymphoma | MNDR-E-MI-14365 |
MNDR | hsa-miR-143-3p | Dementia vascular | MNDR-E-MI-14366 |
MNDR | hsa-miR-143-3p | Tonsil cancer | MNDR-E-MI-14367 |
MNDR | hsa-miR-143-3p | Neuromyelitis optica | MNDR-E-MI-14368 |
MNDR | hsa-miR-143-3p | Psoriasis | MNDR-E-MI-14369 |
MNDR | hsa-miR-143-3p | Degenerative disc disease | MNDR-E-MI-14370 |
MNDR | hsa-miR-143-3p | Acute myelocytic leukemia | MNDR-E-MI-14371 |
MNDR | hsa-miR-143-3p | Colorectal cancer | MNDR-E-MI-14372 |
MNDR | hsa-miR-143-3p | Nasopharynx carcinoma | MNDR-E-MI-14373 |
MNDR | hsa-miR-143-3p | Multiple myeloma | MNDR-E-MI-14374 |
MNDR | hsa-miR-143-3p | Acute lymphoblastic leukemia | MNDR-E-MI-14375 |
MNDR | hsa-miR-143-3p | Obesity | MNDR-E-MI-14376 |
MNDR | hsa-miR-143-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-14377 |
MNDR | hsa-miR-143-3p | Uterine cervical neoplasms | MNDR-E-MI-14378 |
MNDR | hsa-miR-143-3p | Fever | MNDR-E-MI-14379 |
MNDR | hsa-miR-143-3p | Nasopharyngeal cancer | MNDR-E-MI-14380 |
MNDR | hsa-miR-143-3p | Prostatic neoplasms | MNDR-E-MI-14381 |
MNDR | hsa-miR-143-3p | Sleep deprivation | MNDR-E-MI-14382 |
MNDR | hsa-miR-143-3p | Epstein-barr virus infections | MNDR-E-MI-14383 |
MNDR | hsa-miR-143-3p | Subarachnoid hemorrhage traumatic | MNDR-E-MI-14384 |
MNDR | hsa-miR-143-3p | Pituitary acth hypersecretion | MNDR-E-MI-14385 |
MNDR | hsa-miR-143-3p | Stroke lacunar | MNDR-E-MI-14386 |
MNDR | hsa-miR-143-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-14387 |
MNDR | hsa-miR-143-3p | Barrett's carcinogenesis | MNDR-E-MI-14388 |
MNDR | hsa-miR-143-3p | Breast cancer her3+ negative | MNDR-E-MI-14389 |
MNDR | hsa-miR-143-3p | Duke C | MNDR-E-MI-14390 |
RNA Interaction Information
Resource | RNA Symbol | Species | Link | RNALocate ID |
RNAInter | ABCC3 | Homo sapiens | RR00023590 |
TOP